Mounjaro™ (Tirzepatide) is a new and effective dual action drug for patients with type 2 diabetes and obesity
Mounjaro™(Tirzepatide) by the pharmaceutical company Eli Lilly, which received FDA (Food and Drug Administration) approval for type 2 diabetes treatment in May 2022, has successfully passed the third phase of clinical trials as an effective means to reduce weight. The pharmaceutical company has already submitted a request to FDA for registration of Mounjaro™ as a treatment for obesity in adults, and not just a treatment for type 2 diabetes. Request approval at Eli Lilly is expected at the end of 2023.
The active ingredient tirzepatide is the first member of its class of drugs that is a dual agonist of glucagon-like peptide-1 (GLP-1) receptor and glucose-dependent insulinotropic polypeptide (GIP) receptor.
This is a group of hormone-like substances, incretins, which are produced in human intestine in response to food ingestion, using a glucose-dependent mechanism, increase insulin production by pancreas. Approximately 70% of all insulin is released in response to a meal due to the combined action of GLP-1 and GIP.
From the point of weight loss view, the main action also belongs to the activation of glucagon-like peptide-1 (GLP-1) receptors, as a result of which the evacuation of food from the stomach slows down. This leads to decrease in appetite, a long feeling of satiety after eating, which allows you to effectively and gradually reduce weight.
Mounjaro™ (Tirzepatide) is available in five different dosage, allowing to titrate an effective dose and lead to therapeutic levels gradually. The drug is administered parenterally subcutaneously once a week, which is very convenient compared with liraglutide (Saxenda, Victoza), which must be injected daily.
Tirzepatide was compared in pivotal clinical trials with semaglutide (Ozempic) and, accordingly, a placebo group. Several studies were conducted that formed the basis of drug’s registration dossier: SURMOUNT-1, SURPASS-1, SURPASS-2, SURPASS-3, SURPASS-4 and SURPASS-5. More than 13,000 people participated in the third phase of SURPASS-4. So network evidence base of tirzepatida is solid.
The SURPASS-3 study, in addition to excellent blood glucose control, normalization of glycated hemoglobin levels and significant weight loss, showed a significant decrease in liver fat (average 8% over the observation period).
Here are the MRI results of a patient who managed to reduce the amount of fat in liver by 25% and get rid of fatty hepatosis.
This allows us to consider tirzepatide as an effective agent for treatment of metabolic fatty liver disease and the prevention of fibrosis and cirrhosis in overweight patients. The studies compared the level of glucose reduction to Novo Nordisk’s main competitor, Ozempic.
As you can see, Mounjaro™ (Tirzepatide) proved to be more effective in this regard.
Tirzepatide has also been shown in clinical trials to be the most effective weight loss agent in its class. The researchers compared Mounjaro™ with Novo Nordisk’s main competitor Ozempic and Vegovi (semaglutide). As you can see, the results are expected – tirzepatide is more effective in terms of weight loss than semaglutide.
As a conclusion, it can be noted that now the pharmaceutical market has good drugs for weight loss and obesity, but today Mounjaro™ surpasses them all and is comparable in effectiveness to bariatric surgery.
P.S. The record-breaking patient in clinical trials with Mounjaro™ managed to lose 24 kilograms of extra weight.